ONL Therapeutics Looks to IND in 2018
ONL Therapeutics is using the $5 million in Series A funding it obtained in May 2017 to complete and file the investigational new drug application for its lead candidate, ONL 1204, president and CEO John Freshley said during the Company Showcase 3 session at OIS@AAO 2017. ONL 1204 is a first-in-class Fas inhibitor for treatment of retinal detachment, and has orphan drug designation, Freshley noted. The company expects to file the IND in the first half of 2018, with plans to commence a Phase I/II dose escalation trial in the second half of 2018 and launch a Phase I/II dose-expansion trial in 2019, he added.